The combination of TLR9 agonists with the PD-1/PD-L1 blockade has shown an elevated number of multifunctional tumor antigen-specific T cells expressing TNF and IFNγ, and a proportion of memory precursor effector cells [162]. This evidence concerns the gene IFNG and neoplasm.